Harvard Bioscience, Inc. to Participate in Two Investor Conferences in March 2025

Rhea-AI Summary

Harvard Bioscience (Nasdaq: HBIO) has announced its participation in two major investor conferences in March 2025. The company's leadership team, including Chairman and CEO Jim Green and CFO Jennifer Cote, will attend:

1. The 37th Annual Roth Conference (March 16-18, 2025) at the Laguna Cliffs Marriott Resort in Dana Point, CA. Management will conduct one-on-one meetings and participate in a Fireside Chat on March 17th at 10 a.m. PT.

2. The KeyBanc Capital Markets Healthcare Forum, a virtual event on March 19, 2025, featuring one-on-one meetings and a Fireside Chat with Paul Knight at 3:45 p.m. ET.

Both events will be webcast live on the company's investor relations website.

HOLLISTON, Mass., March 12, 2025 (GLOBE NEWSWIRE) -- Harvard Bioscience, Inc. (Nasdaq: HBIO) today announced that Jim Green, Chairman and Chief Executive Officer, and Jennifer Cote, Chief Financial Officer, will participate in two investor conferences in March 2025:

• The 37th Annual Roth Conference is being held on March 16-18, 2025, at the Laguna Cliffs Marriott Resort in Dana Point, CA. On March 17^th, management will host one-on-one meetings and is scheduled for a Fireside Chat on the same day starting at 10 a.m. PT (1:00 p.m. ET). The live webcast is available on HBIO’s website at https://investor.harvardbioscience.com/events-and-presentations. Investors interested in scheduling a one-on-one meeting can contact oneonone@roth.com.
  
  
• The KeyBanc Capital Markets Healthcare Forum is a virtual event scheduled for March 19, 2025. Management will host one-on-one meetings and is also scheduled for a Fireside Chat with Paul Knight, KeyBanc Capital Markets, on the same day starting at 3:45 p.m. ET. The live webcast is available on HBIO’s website at https://investor.harvardbioscience.com/events-and-presentations. Investors interested in scheduling a one-on-one meeting can contact kbcmhealthcareconferenceteam@key.com.
  

About Harvard Bioscience, Inc.
Harvard Bioscience, Inc. is a leading developer, manufacturer and seller of technologies, products and services that enable fundamental advances in life science applications, including research, pharmaceutical and therapy discovery, bio-production and preclinical testing for pharmaceutical and therapy development. Our customers range from renowned academic institutions and government laboratories to the world’s leading pharmaceutical, biotechnology and contract research organizations. With operations in North America, Europe, and China, we sell through a combination of direct and distribution channels to customers around the world. For more information, please visit our website at www.harvardbioscience.com 

Company Contact: 
Harvard Bioscience 
Jennifer Cote, Chief Financial Officer 
(508) 893-3120 

Investor Contacts: 
Three Part Advisors 
Sandy Martin / Erol Girgin
HBIO@threepa.com 
(214) 616-2207 

FAQ

When is Harvard Bioscience (HBIO) presenting at the Roth Conference in March 2025?

HBIO will present at the Roth Conference on March 17, 2025, at 10:00 AM PT (1:00 PM ET) through a Fireside Chat format.

How can investors watch HBIO's March 2025 conference presentations?

Investors can watch the live webcasts of both presentations on HBIO's website at investor.harvardbioscience.com/events-and-presentations.

What investor conferences is HBIO attending in March 2025?

HBIO is participating in the 37th Annual Roth Conference (March 16-18) and the KeyBanc Capital Markets Healthcare Forum (March 19).

How can investors schedule one-on-one meetings with HBIO management at these conferences?

For Roth Conference meetings, contact oneonone@roth.com. For KeyBanc Forum meetings, contact kbcmhealthcareconferenceteam@key.com.

Which HBIO executives are participating in the March 2025 investor conferences?

Chairman and CEO Jim Green and CFO Jennifer Cote will represent HBIO at both conferences.